For US Patients

Get Support:
Enroll or Sign In

How TREMFYA® works

See the science

How to take TREMFYA®

Discover dosing

Start and stay on TREMFYA®

Learn about support

Explore TREMFYA®

In a trial of patients who received TREMFYA® subcutaneously for initial and maintenance doses:

FAST ACTING

12 weeks

~3 out of 10 patients achieved endoscopic response at 12 weeks.†

~5 out of 10 patients achieved clinical remission.

Decreases in abdominal pain and
stool frequency were observed as early as 4 weeks.

LONG LASTING

1 year

~6 out of 10 patients achieved clinical remission.

Clinical remission means remission of symptoms.

SOME
PATIENTS HAD

VISIBLE
HEALING

OF THE INTESTINAL LINING†

~3 out of 10 patients were in endoscopic remission† at 1 year.

There is no cure for CD.

†Endoscopic remission and endoscopic response are based on areas visualized on colonoscopy, which may not represent the deeper bowel layer or all areas.

AT 2 YEARS

~5 out of 10 patients were in clinical remission.‡

‡The same patients may not have been in remission at each timepoint. After 1 year, patients and healthcare providers knew that TREMFYA® was used. This may have increased results.

See the results

Results may vary.
Ask your healthcare provider if TREMFYA® is right for you.

Download discussion guide
200 mg/2 mL TREMFYA® PEN for subcutaneous use

TREMFYA® is the only IL-23 blocker for CD to offer self-administration from the start

You and your healthcare provider will discuss how you start TREMFYA® for CD:

Subcutaneous (SC) injections under the skin following training*

OR

Intravenous (IV) infusions
through a vein in the arm

Explore your options

*If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA®
at home, you should receive training on the right way to prepare and inject TREMFYA®.
Do not try to inject yourself until you have been trained by your healthcare provider.

CD=Crohn’s disease; IL=interleukin.